Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Provided By GlobeNewswire
Last update: Mar 27, 2025
BBI-355 Phase 1/2 POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second half of 2025
Novel Kinesin program progressing toward development candidate nomination by mid-2025, with IND submission expected in the first half of 2026
Read more at globenewswire.com
